ReviewInternational journal of hematology2013
Multiple myeloma-initiating cells.
Review in International journal of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Network-Based Bioinformatics Reveal Microenvironment-Driven Cell-to-Cell Communication in the Progression of Multiple Myeloma.International journal of molecular sciences · 2026Article
- Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.Frontiers in immunology · 2026Article
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.Nature communications · 2024Article
- Cancer cell targeting by CAR-T cells: A matter of stemness.Frontiers in molecular medicine · 2022Review
- Expression of activated integrin β7 in multiple myeloma patients.International journal of hematology · 2021Article
- Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects.Acta pharmaceutica Sinica. B · 2021Review
- Chimeric antigen receptor T-cell therapy for multiple myeloma.International journal of hematology · 2020Review
- Chimeric antigen receptor T cell therapy for multiple myeloma.Inflammation and regeneration · 2019Review
- Identification of the xenograft and its ascendant sphere-forming cell line as belonging to EBV-induced lymphoma, and characterization of the status of sphere-forming cells.Cancer cell international · 2019Article
- Nanotherapeutics for multiple myeloma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2018Review
- Anterior mediastinum invasion by multiple myeloma: A case report.Oncology letters · 2017Article
- The myeloma stem cell concept, revisited: from phenomenology to operational terms.Haematologica · 2016Review
- Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.International journal of hematology · 2016Review
- The Tao of myeloma.Blood · 2014Review
- Ikaros fingers on lymphocyte differentiation.International journal of hematology · 2014Review
- Potential role of daratumumab in the treatment of multiple myeloma.OncoTargets and therapy · 2014Review
- A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit.Frontiers in immunology · 2013Review
- Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells. As in other cancers, MM plasma cells are thought to be derived from MM-initiating cells, although these remain unidentified. MM patients harbor phenotypic CD19(+) B cells expressing the immunoglobulin gene sequence and the idiotype unique to the individual myeloma clone. Some previous studies have reported that CD19(+) clonotypic B cells can serve as MM-initiating cells. However, we and another group have recently showed that CD19(+) B cells from many MM patients do not reconstitute MM disease upon transplantation into NOD/SCID IL2Rγc(-/-) mice. In the SCID-rab and SCID-hu models, which enable engraftment of human MM in vivo, CD19(-)CD38(++) plasma cells engrafted and rapidly propagated MM, while engraftment of CD19(+) B cells was not detected. Both CD138(-) and CD138(+) plasma cells have the potential to propagate MM clones in vivo in the absence of CD19(+) B cells. Distinct from acute myeloid leukemia-initiating cells, which are derived from undifferentiated stem or progenitor cells, MM-initiating cells are derived from plasma cells, which are terminally differentiated cells. An improved understanding of how the bone marrow microenvironment supports MM-initiating plasma cells, which can initiate MM disease in the SCID-hu (or rab) model, is thus now essential.
Indexed as
Identifiers
23420183What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.